Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 402.50p 395.00p 410.00p 402.50p 402.50p 402.50p 63,165 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 67.2 13.9 14.2 28.4 270.16

Eco Animal Health Share Discussion Threads

Showing 926 to 950 of 1000 messages
Chat Pages: 40  39  38  37  36  35  34  33  32  31  30  29  Older
DateSubjectAuthorDiscuss
02/7/2018
11:55
Re Aivlosin the results statement includes the following encouraging words: "Substantial on-going product development covering more formulations, species and diseases is expected to substantially further increase it's revenue generating potential."
aimingupward2
02/7/2018
10:24
Good results imo
cascudi
02/7/2018
08:45
Only blue on my screen amongst a see of red. Would be good to see stronger sales in the US in second half and anything that could improve margins would also be good! More importantly, it will be interesting to see what strategy they adopt for spending the cash. A move in to vaccines may be good in terms of the size of the opportunity but they will need to acquire the necessary expertise. And as they mention there is indeed a lot of consolidation in the chemicals sector so will they be a target?
audigger
02/7/2018
07:10
Share price seems to have gone up a little at the bell though, so results seem to have gone down OK.
topvest
02/7/2018
07:07
I suppose it explains the recent weakness in the share price though. On an actual trailing P/E of 35 maybe moving down to 27 if they now achieve 20p EPS in current financial year. A quality business, but hardly cheap. Dividend yield is 2% though which is not bad.
topvest
02/7/2018
07:02
"Net profit in China increased by more than 61 per cent over the same period last year, once again reflecting the effectiveness of our overall strategy."....only about half their profit whereas some other key markets that they own 100% of were softer. It's always been a bit volatile on that front, so I would tend to agree that these numbers better reflect the underlying position.... 9.4% increase in sales to £67.2m (2017: £61.4m) 12% increase in operating profit to £14.1m (2017: £12.6m) 15% increase in adjusted EBITDA to £19.6m (2017: £17.1m) 30% increase in dividend to 9.2p (2017: 7.1p) Strong cash generation from operations leaving net cash of £21.3 million at year end (2017: £20.6) Aivlosin® sales up almost 14%
topvest
02/7/2018
06:52
It's two things from what I can see: higher tax charge and mix of profits which are more in their non-wholly owned subsidiaries this year, particularly China. Look at the NCI number!
topvest
02/7/2018
06:43
I would say an excellent and welcome increase in the dividend payment at 30%. What I don’t understand, yet anyway, is why the eps has come in below last year’s figure. I’ve seen any comment on that on first skim reading, but the cash flow and outlook are still good.
aimingupward2
02/7/2018
06:39
Yes, only solid is how I would describe it. Headline numbers are good. Higher tax charge and minority interest profits have negatively impacted the EPS number though which is only 14p and seems to be much lower than the consensus of 20p. Looks like the currency tailwind in the prior year was more of a headwind in the current year. Underlying growth seems to have moderated to 15% or so. Happy to hold though as still growing nicely overall.
topvest
02/7/2018
06:11
And here they are! Solid. Looks like they will use cash for acquisition of molecules, companies or both. Reasonable uplift in the divi
audigger
28/6/2018
19:13
Yes that's the mix of the 16 and the near 24. Quite rare to find a spread that big I find. I wonder what has gone on in terms of expectations setting. A bit concerned that many institutional investors will be looking for the 24 and the 20 or below may be disappointing
pireric
28/6/2018
07:45
Well eps last year was 16.35p, so would have thought closer to 24p is likely. It looks like the consensus eps is 20p for 2018.
jimbowen30
27/6/2018
19:38
My one concern is what the brokers have. Peel Hunt are way ahead of N+1 on EPS and yet both of them seem to actively cover Eco. I'm talking 23p+ for Peel Hunt and yet N+1 are way back at 16p EPS.... Anyone got the foggiest which one looks most reasonable? I don't have access to the full models so can't see why there is a divergence. If it is the 16p one that would be desperately disappointing IMO, and the PE would be well over 30x. If it's 23p then very different story altogether. Split the difference - if it came in at 20p, that's probably good to neutral
pireric
27/6/2018
08:21
Buying in, or topping up, ahead of the results would seem to be a pretty safe bet then.
aimingupward2
26/6/2018
22:05
I'd be surprised if the results aren't record breaking again. Hopefully they will prompt a re-rating to 800 plus!
audigger
26/6/2018
18:28
I'd have thought next week. Pattern seems to be right at the end of June to right at the start of July. 2nd/3rd July sounds about right to me so next Monday or Tuesday I guess
pireric
26/6/2018
07:41
Results must be due this week?
jimbowen30
25/6/2018
19:40
Just an uncrossing auction trade. They always reverse on the trading session after as its not a fair reflection of the market. Same can happen on the upside as on the downside. Happens on lots of illiquid stocks
pireric
25/6/2018
10:15
Some after hours transactions at 482p on Friday. Someone who knows what this means might be able to explain. I was beginning to think there was a leaky results ship about. Been hit a few times lately where the price dropped away ahead of poor results...hope it doesn’t happen again here!
steve3sandal
25/6/2018
07:46
Some very strange movements in the share price When did it drop 25p? Thought it finished flat on Friday? Anyhow, it seems to have jumped straight back on zero volume today. Weird!
audigger
20/6/2018
14:41
I, too, am looking forward to encouragingly good results, but would also like to learn more about: - the gradual replacement of distributors by EAH's own staff, which would increase margins. - a possible second factory for the production of Aivlosin, reducing dependence on a single unit in China. - increasing prices achieved for Aivlosin and improving EBIDTA margins. - an update on the authorisation of Aivlosin for 'other species'. _ more about the ECO-PHARM joint venture and the business scope and opportunities for their range of vaccine products.
aimingupward2
19/6/2018
19:24
Back down to the trough of early this year. Results should be out soon and show nice numbers. To add further, or not, that's the question Expecting EPS of 20p, so +25% y/y, obviously this being negatively impacted by registration costs needing to be amortised extremely quickly, and so EBITDA the more telling figure. Should be good and £ weakness hopefully already flowing into an extra tailwind for this financial year.
pireric
05/6/2018
11:02
If history is our guide I think PL will be pleased to see the cash pile increase. Mostly reinvest cashflows, pay out a little, save a little. Same story at Anpario. Been watching this play out for years, since Amati VCT Investment. I try to do the same!
steve3sandal
05/6/2018
10:02
Take that as a no :0). Happy enough if these are in line with expectations as last year was a very strong base period to perform against (FX tailwinds turning to headwinds etc). Still wondering what on earth they're going to do with the cash pile, any thoughts anyone? What would you like to see them do?
pireric
02/6/2018
08:22
Anyone seen the Peel hunt note from weds/thurs where they reiterated their buy rating?
pireric
Chat Pages: 40  39  38  37  36  35  34  33  32  31  30  29  Older
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181214 02:34:24